 Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program EAP evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. NYSE:AIM is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. 